<p>根据 AlphaQuest LLC 在最近向美国证券交易委员会提交的 13F 表格，该公司在第一季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的持股比例提高了 941.6%。在该季度购买了额外的 10,085 股后，该机构投资者持有 11,156 股该公司的股票。AlphaQuest LLC 在艾伯维的持股在最近的报告期末价值为 2,337,000 美元。</p>
<ul>
<li>艾伯维股票关注突破，管道和利润增长</li>
</ul>
<p>其他机构投资者最近也买卖了该公司的股票。Leslie Global Wealth LLC 在第一季度将其在艾伯维的持股提高了 2.2%。Leslie Global Wealth LLC 现在拥有 3,333 股该公司的股票，价值为 698,000 美元，此前在上个季度购买了 72 股。Strategies Wealth Advisors LLC 在第一季度获得了艾伯维的新股份，价值约为 435,000 美元。Allstate Corp 在第一季度将其在艾伯维的持股提高了 16.3%。Allstate Corp 现在拥有 61,060 股该公司的股票，价值为 12,793,000 美元，此前在上个季度购买了 8,561 股。Laffer Tengler Investments Inc.在第一季度将其在艾伯维的持股提高了 2.6%。Laffer Tengler Investments Inc.现在拥有 66,038 股该公司的股票，价值为 13,836,000 美元，此前在上个季度购买了 1,657 股。最后，MAS Advisors LLC 在第一季度获得了艾伯维的新股份，价值约为 220,000 美元。机构投资者持有该公司 70.23% 的股票。</p>
<h2>华尔街分析师观点</h2>
<p>多家研究公司最近对 ABBV 发布了报告。Guggenheim 将艾伯维股票的目标价从 216.00 美元上调至 227.00 美元，并在 8 月 1 日的报告中给予该公司 “买入” 评级。法国巴黎银行在 5 月 8 日的报告中将艾伯维股票的评级上调至 “持有”。Wall Street Zen 在 5 月 22 日的报告中将艾伯维股票的评级从 “强烈买入” 下调至 “买入”。美国银行在 6 月 9 日的报告中将艾伯维股票的目标价上调至 204.00 美元，并给予该公司 “持有” 评级。最后，摩根士丹利在 8 月 1 日的报告中将艾伯维股票的目标价从 250.00 美元上调至 255.00 美元，并给予该公司 “增持” 评级。五位分析师给予该股票 “强烈买入” 评级，十六位给予 “买入” 评级，六位给予 “持有” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 214.95 美元。</p>
<ul>
<li>3 家生物科技巨头受益于美国销售和政策变化</li>
</ul>
<p><strong>查看我们最新的艾伯维股票报告</strong></p>
<h2>艾伯维股票上涨 0.2%</h2>
<p>艾伯维股票在周五开盘价为 209.5410 美元。艾伯维公司 52 周低点为 163.81 美元，52 周高点为 218.66 美元。该公司的 50 日移动平均线为 192.45 美元，200 日移动平均线为 192.81 美元。公司的债务与股本比率为 44.14，速动比率为 0.61，流动比率为 0.74。该股票的市值为 3701.7 亿美元，市盈率为 99.78，市盈增长比率为 1.34，贝塔值为 0.50。</p>
<ul>
<li>如果你想购买艾伯维但没有，现在仍然有机会购买</li>
</ul>
<p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 7 月 31 日发布了季度财报。该公司报告每股收益为 2.97 美元，低于市场共识预期的 3.24 美元，差额为 0.27 美元。艾伯维的股本回报率为 699.66%，净利润率为 6.45%。该公司在本季度的收入为 154.2 亿美元，而市场共识预期为 149.3 亿美元。在去年同期，该公司每股收益为 2.65 美元。与去年同期相比，该公司的季度收入增长了 6.6%。作为一个整体，卖方分析师预测艾伯维公司今年将发布 12.31 美元的每股收益。</p>
<h2>艾伯维宣布分红</h2>
<p>该公司最近还披露了季度分红，已于 8 月 15 日支付。7 月 15 日的股东获得了 1.64 美元的分红。该分红的除息日为 7 月 15 日。这代表着每年 6.56 美元的分红和 3.1% 的分红收益率。艾伯维的分红支付比率目前为 312.38%。</p>
<h2>艾伯维内部活动</h2>
<p>在其他新闻中，执行副总裁 Azita Saleki-Gerhardt 在 8 月 12 日的交易中出售了 42,370 股该公司的股票。股票以平均价格 198.42 美元出售，总价值为 8,407,055.40 美元。交易完成后，该执行副总裁持有 177,292 股该公司的股票，价值为 35,178,278.64 美元。这代表着其持股比例减少了 19.29%。该交易已在向 SEC 的备案中披露，相关信息可通过此链接获取。此外，执行副总裁 Nicholas Donoghoe 在 8 月 5 日的交易中出售了 13,295 股该公司的股票。股票以平均价格 198.51 美元出售，总价值为 2,639,190.45 美元。交易完成后，该执行副总裁直接持有 58,247 股该公司的股票，价值为 11,562,611.97 美元。这代表着其持股比例减少了 18.58%。该销售的披露信息可在此处找到。公司内部人士持有该公司 0.25% 的股票。</p>
<h2>艾伯维公司简介</h2>
<p>（免费报告）</p>
<p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供的药品包括：Humira，用于治疗自身免疫性疾病和肠道贝赫切特病以及脓皮病；Skyrizi，用于治疗中度至重度斑块型银屑病、银屑病性关节炎和克罗恩病；Rinvoq，用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica，用于治疗成人血癌患者；Epkinly，用于治疗淋巴瘤；Elahere，用于治疗癌症；Venclexta/Venclyxto，用于治疗血癌。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，胜过艾伯维</li>
<li>现在值得购买的三只巨头成长股</li>
<li>小市值，大潜力：你应该了解的三家科技颠覆者</li>
<li>三只值得长期持有的房地产投资信托基金</li>
<li>在盈利未达预期后，沃尔玛仍然是顶级消费品投资选择</li>
<li>什么是便士股票？全面指南</li>
<li>思科如何为投资者构建新的增长故事</li>
</ul>
<p><strong>想知道其他对艾伯维持有投资的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取艾伯维公司（NYSE:ABBV - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
<p>在考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在市场广泛关注之前购买……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>AlphaQuest LLC 在第一季度显著增加了对艾伯维（AbbVie Inc.）的持股，增幅达到 941.6%，额外购买了 10,085 股，使其总持股量达到 11,156 股，市值为 234 万美元。其他机构投资者也提高了他们的持股。分析师对艾伯维的股票评级褒贬不一，平均目标价为 214.95 美元。该公司报告第二季度每股收益为 2.97 美元，未达到预期，但收入同比增长了 6.6%。艾伯维宣布季度股息为 1.64 美元，收益率为 3.1%</p>

<p>AlphaQuest LLC raised its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 941.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 11,156 shares of the company's stock after buying an additional 10,085 shares during the quarter. AlphaQuest LLC's holdings in AbbVie were worth $2,337,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根据 AlphaQuest LLC 在最近向美国证券交易委员会提交的 13F 表格，该公司在第一季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的持股比例提高了 941.6%。在该季度购买了额外的 10,085 股后，该机构投资者持有 11,156 股该公司的股票。AlphaQuest LLC 在艾伯维的持股在最近的报告期末价值为 2,337,000 美元。</p>
</div><ul>
<li>AbbVie Stock Eyes Breakout as Pipeline and Profits Grow</li>
</ul>
<div class="lb-trans"><ul>
<li>艾伯维股票关注突破，管道和利润增长</li>
</ul>
</div><p>Other institutional investors have also recently bought and sold shares of the company. Leslie Global Wealth LLC raised its holdings in shares of AbbVie by 2.2% in the first quarter. Leslie Global Wealth LLC now owns 3,333 shares of the company's stock valued at $698,000 after purchasing an additional 72 shares during the last quarter. Strategies Wealth Advisors LLC acquired a new stake in shares of AbbVie in the first quarter valued at approximately $435,000. Allstate Corp raised its holdings in shares of AbbVie by 16.3% in the first quarter. Allstate Corp now owns 61,060 shares of the company's stock valued at $12,793,000 after purchasing an additional 8,561 shares during the last quarter. Laffer Tengler Investments Inc. raised its holdings in shares of AbbVie by 2.6% in the first quarter. Laffer Tengler Investments Inc. now owns 66,038 shares of the company's stock valued at $13,836,000 after purchasing an additional 1,657 shares during the last quarter. Finally, MAS Advisors LLC acquired a new stake in shares of AbbVie in the first quarter valued at approximately $220,000. Institutional investors own 70.23% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者最近也买卖了该公司的股票。Leslie Global Wealth LLC 在第一季度将其在艾伯维的持股提高了 2.2%。Leslie Global Wealth LLC 现在拥有 3,333 股该公司的股票，价值为 698,000 美元，此前在上个季度购买了 72 股。Strategies Wealth Advisors LLC 在第一季度获得了艾伯维的新股份，价值约为 435,000 美元。Allstate Corp 在第一季度将其在艾伯维的持股提高了 16.3%。Allstate Corp 现在拥有 61,060 股该公司的股票，价值为 12,793,000 美元，此前在上个季度购买了 8,561 股。Laffer Tengler Investments Inc.在第一季度将其在艾伯维的持股提高了 2.6%。Laffer Tengler Investments Inc.现在拥有 66,038 股该公司的股票，价值为 13,836,000 美元，此前在上个季度购买了 1,657 股。最后，MAS Advisors LLC 在第一季度获得了艾伯维的新股份，价值约为 220,000 美元。机构投资者持有该公司 70.23% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of research firms have recently issued reports on ABBV. Guggenheim lifted their price objective on shares of AbbVie from $216.00 to $227.00 and gave the company a &#34;buy&#34; rating in a report on Friday, August 1st. BNP Paribas upgraded shares of AbbVie to a &#34;hold&#34; rating in a report on Thursday, May 8th. Wall Street Zen downgraded shares of AbbVie from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Thursday, May 22nd. Bank of America upped their price objective on shares of AbbVie to $204.00 and gave the company a &#34;hold&#34; rating in a report on Monday, June 9th. Finally, Morgan Stanley upped their price objective on shares of AbbVie from $250.00 to $255.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, August 1st. Five analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $214.95.</p>
<div class="lb-trans"><p>多家研究公司最近对 ABBV 发布了报告。Guggenheim 将艾伯维股票的目标价从 216.00 美元上调至 227.00 美元，并在 8 月 1 日的报告中给予该公司 “买入” 评级。法国巴黎银行在 5 月 8 日的报告中将艾伯维股票的评级上调至 “持有”。Wall Street Zen 在 5 月 22 日的报告中将艾伯维股票的评级从 “强烈买入” 下调至 “买入”。美国银行在 6 月 9 日的报告中将艾伯维股票的目标价上调至 204.00 美元，并给予该公司 “持有” 评级。最后，摩根士丹利在 8 月 1 日的报告中将艾伯维股票的目标价从 250.00 美元上调至 255.00 美元，并给予该公司 “增持” 评级。五位分析师给予该股票 “强烈买入” 评级，十六位给予 “买入” 评级，六位给予 “持有” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 214.95 美元。</p>
</div><ul>
<li>3 Biotech Giants Gaining From U.S. Sales and Policy Shifts</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家生物科技巨头受益于美国销售和政策变化</li>
</ul>
</div><p><strong>View Our Latest Stock Report on ABBV</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的艾伯维股票报告</strong></p>
</div><h2>AbbVie Trading Up 0.2%</h2>
<div class="lb-trans"><h2>艾伯维股票上涨 0.2%</h2>
</div><p>Shares of AbbVie stock opened at $209.5410 on Friday. AbbVie Inc. has a 52-week low of $163.81 and a 52-week high of $218.66. The firm has a 50-day moving average of $192.45 and a 200-day moving average of $192.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The stock has a market cap of $370.17 billion, a PE ratio of 99.78, a PEG ratio of 1.34 and a beta of 0.50.</p>
<div class="lb-trans"><p>艾伯维股票在周五开盘价为 209.5410 美元。艾伯维公司 52 周低点为 163.81 美元，52 周高点为 218.66 美元。该公司的 50 日移动平均线为 192.45 美元，200 日移动平均线为 192.81 美元。公司的债务与股本比率为 44.14，速动比率为 0.61，流动比率为 0.74。该股票的市值为 3701.7 亿美元，市盈率为 99.78，市盈增长比率为 1.34，贝塔值为 0.50。</p>
</div><ul>
<li>If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>如果你想购买艾伯维但没有，现在仍然有机会购买</li>
</ul>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing the consensus estimate of $3.24 by ($0.27). AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm had revenue of $15.42 billion for the quarter, compared to the consensus estimate of $14.93 billion. During the same period in the prior year, the company earned $2.65 EPS. The company's revenue for the quarter was up 6.6% compared to the same quarter last year. As a group, sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 7 月 31 日发布了季度财报。该公司报告每股收益为 2.97 美元，低于市场共识预期的 3.24 美元，差额为 0.27 美元。艾伯维的股本回报率为 699.66%，净利润率为 6.45%。该公司在本季度的收入为 154.2 亿美元，而市场共识预期为 149.3 亿美元。在去年同期，该公司每股收益为 2.65 美元。与去年同期相比，该公司的季度收入增长了 6.6%。作为一个整体，卖方分析师预测艾伯维公司今年将发布 12.31 美元的每股收益。</p>
</div><h2>AbbVie Announces Dividend</h2>
<div class="lb-trans"><h2>艾伯维宣布分红</h2>
</div><p>The company also recently disclosed a quarterly dividend, which was paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th were paid a $1.64 dividend. The ex-dividend date of this dividend was Tuesday, July 15th. This represents a $6.56 annualized dividend and a dividend yield of 3.1%. AbbVie's dividend payout ratio is currently 312.38%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，已于 8 月 15 日支付。7 月 15 日的股东获得了 1.64 美元的分红。该分红的除息日为 7 月 15 日。这代表着每年 6.56 美元的分红和 3.1% 的分红收益率。艾伯维的分红支付比率目前为 312.38%。</p>
</div><h2>Insider Activity at AbbVie</h2>
<div class="lb-trans"><h2>艾伯维内部活动</h2>
</div><p>In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the transaction, the executive vice president owned 177,292 shares of the company's stock, valued at $35,178,278.64. This represents a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Nicholas Donoghoe sold 13,295 shares of the company's stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the transaction, the executive vice president directly owned 58,247 shares of the company's stock, valued at $11,562,611.97. This represents a 18.58% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.25% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Azita Saleki-Gerhardt 在 8 月 12 日的交易中出售了 42,370 股该公司的股票。股票以平均价格 198.42 美元出售，总价值为 8,407,055.40 美元。交易完成后，该执行副总裁持有 177,292 股该公司的股票，价值为 35,178,278.64 美元。这代表着其持股比例减少了 19.29%。该交易已在向 SEC 的备案中披露，相关信息可通过此链接获取。此外，执行副总裁 Nicholas Donoghoe 在 8 月 5 日的交易中出售了 13,295 股该公司的股票。股票以平均价格 198.51 美元出售，总价值为 2,639,190.45 美元。交易完成后，该执行副总裁直接持有 58,247 股该公司的股票，价值为 11,562,611.97 美元。这代表着其持股比例减少了 18.58%。该销售的披露信息可在此处找到。公司内部人士持有该公司 0.25% 的股票。</p>
</div><h2>AbbVie Company Profile</h2>
<div class="lb-trans"><h2>艾伯维公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供的药品包括：Humira，用于治疗自身免疫性疾病和肠道贝赫切特病以及脓皮病；Skyrizi，用于治疗中度至重度斑块型银屑病、银屑病性关节炎和克罗恩病；Rinvoq，用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica，用于治疗成人血癌患者；Epkinly，用于治疗淋巴瘤；Elahere，用于治疗癌症；Venclexta/Venclyxto，用于治疗血癌。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>3 Monster Growth Stocks to Buy Now</li>
<li>Small Cap, Big Potential: 3 Tech Disruptors You Should Know About</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>After Earnings Miss, Walmart Is Still a Top Consumer Staples Play</li>
<li>What is a penny stock? A comprehensive guide</li>
<li>How Cisco Is Building a New Growth Story for Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过艾伯维</li>
<li>现在值得购买的三只巨头成长股</li>
<li>小市值，大潜力：你应该了解的三家科技颠覆者</li>
<li>三只值得长期持有的房地产投资信托基金</li>
<li>在盈利未达预期后，沃尔玛仍然是顶级消费品投资选择</li>
<li>什么是便士股票？全面指南</li>
<li>思科如何为投资者构建新的增长故事</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABBV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对艾伯维持有投资的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取艾伯维公司（NYSE:ABBV - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在市场广泛关注之前购买……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

AlphaQuest LLC 购买了 10,085 股艾伯维公司（AbbVie Inc.）的股票 $ABBV